Zydus Life Eyes US Biopharma Firm Ardelyx Acquisition, Plans QIP for Funding

• Zydus Lifesciences Ltd. is reportedly in talks to acquire US biopharma firm Ardelyx or a controlling stake/key molecules.
• Zydus Life plans to raise up to ₹5,000 crore via Qualified Institutional Placement (QIP) to partially fund the acquisition.
• Ardelyx, with a market capitalization of $1.6 billion, has two commercial products: IBSRELA and XYPHOZAH.
• IBSRELA, a key product for Ardelyx, is projected to generate $410-$430 million in revenue in 2026, potentially reaching $1 billion by 2029.
• Zydus Life previously stated its QIP objective was to deleverage its balance sheet and explore opportunities in US specialty business, including gastroenterology, CNS, and cardiology.

Why It Matters: Zydus Life is exploring a significant acquisition of US biopharma Ardelyx, backed by a planned QIP.